Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis | 6 | 2023 | 238 | 1.760 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2015 | 34 | 0.510 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 259 | 0.510 |
Why?
|
| Aromatase Inhibitors | 2 | 2015 | 78 | 0.500 |
Why?
|
| Physicians | 1 | 2023 | 955 | 0.410 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 978 | 0.380 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 350 | 0.380 |
Why?
|
| Bone and Bones | 1 | 2013 | 317 | 0.330 |
Why?
|
| Arthropathy, Neurogenic | 1 | 2007 | 2 | 0.260 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 2382 | 0.250 |
Why?
|
| Diabetes Complications | 1 | 2007 | 224 | 0.220 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2023 | 46 | 0.180 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 91 | 0.150 |
Why?
|
| Family Practice | 1 | 2023 | 407 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2025 | 2588 | 0.150 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 6066 | 0.140 |
Why?
|
| Hyperparathyroidism | 1 | 2017 | 11 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 288 | 0.130 |
Why?
|
| RNA Splice Sites | 1 | 2017 | 51 | 0.130 |
Why?
|
| Aged | 7 | 2025 | 26153 | 0.130 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2017 | 40 | 0.120 |
Why?
|
| Blood Glucose | 2 | 2025 | 2341 | 0.120 |
Why?
|
| Abdominal Fat | 1 | 2017 | 51 | 0.120 |
Why?
|
| Bone Density Conservation Agents | 2 | 2019 | 82 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 36 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 77 | 0.120 |
Why?
|
| Hyperglycemia | 1 | 2020 | 379 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2023 | 1371 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 712 | 0.120 |
Why?
|
| Diphosphonates | 2 | 2013 | 68 | 0.120 |
Why?
|
| Point Mutation | 1 | 2017 | 240 | 0.120 |
Why?
|
| Bone Density | 2 | 2017 | 487 | 0.120 |
Why?
|
| SEER Program | 1 | 2017 | 229 | 0.120 |
Why?
|
| Muscle Weakness | 1 | 2016 | 92 | 0.110 |
Why?
|
| Carcinoma | 1 | 2017 | 225 | 0.110 |
Why?
|
| Hand Strength | 1 | 2016 | 144 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 389 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 383 | 0.110 |
Why?
|
| Osteochondroma | 1 | 2015 | 10 | 0.110 |
Why?
|
| Toes | 1 | 2015 | 16 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 321 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 193 | 0.100 |
Why?
|
| Humans | 17 | 2025 | 145474 | 0.100 |
Why?
|
| Middle Aged | 9 | 2025 | 36215 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 1323 | 0.090 |
Why?
|
| Adiposity | 1 | 2017 | 532 | 0.090 |
Why?
|
| Mass Screening | 1 | 2020 | 1360 | 0.090 |
Why?
|
| Male | 10 | 2025 | 72842 | 0.080 |
Why?
|
| Cartilage, Articular | 1 | 2015 | 349 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 8333 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 2028 | 0.070 |
Why?
|
| Survival Rate | 1 | 2013 | 2090 | 0.070 |
Why?
|
| Potassium | 1 | 2009 | 152 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 1097 | 0.060 |
Why?
|
| Blood Sedimentation | 1 | 2007 | 37 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2009 | 328 | 0.060 |
Why?
|
| Cellulitis | 1 | 2007 | 54 | 0.060 |
Why?
|
| Adult | 5 | 2017 | 40777 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2007 | 89 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2007 | 316 | 0.060 |
Why?
|
| Edema | 1 | 2007 | 125 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2007 | 116 | 0.060 |
Why?
|
| Foot | 1 | 2007 | 103 | 0.060 |
Why?
|
| United States | 1 | 2023 | 16098 | 0.060 |
Why?
|
| Female | 7 | 2025 | 78844 | 0.050 |
Why?
|
| Exercise | 1 | 2017 | 2198 | 0.050 |
Why?
|
| Radiography | 1 | 2007 | 852 | 0.050 |
Why?
|
| Hypoglycemic Agents | 2 | 2025 | 1399 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 443 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 519 | 0.050 |
Why?
|
| Risk Factors | 2 | 2016 | 10885 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1508 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2009 | 749 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2007 | 428 | 0.040 |
Why?
|
| Quality of Life | 1 | 2013 | 3204 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 2214 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 3904 | 0.040 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2025 | 701 | 0.040 |
Why?
|
| Hypertension | 1 | 2007 | 1273 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2016 | 143 | 0.030 |
Why?
|
| Anthropometry | 1 | 2016 | 206 | 0.030 |
Why?
|
| Income | 1 | 2016 | 202 | 0.030 |
Why?
|
| Hospitalization | 1 | 2025 | 2460 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 924 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1707 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1581 | 0.020 |
Why?
|
| Imidazoles | 1 | 2012 | 247 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 2105 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 3342 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2445 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2009 | 409 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2023 | 17291 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 2134 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 1210 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 1779 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 14218 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 6013 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 11772 | 0.010 |
Why?
|